A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

Inclusion Criteria:

- Male or non-pregnant and non-breast feeding female

- Females of childbearing potential must have a serum β-human chorionic gonadotropin
(β-hCG) level consistent with non-pregnant state and agree to use (and/or have their
partner use) two acceptable methods of birth control beginning at screening,
throughout the trial (including washout intervals between treatment periods) and
until after the post-study follow-up visit

- Females not of childbearing potential must be either a) postmenopausal (have not had
a menstrual period for at least 1 year and have a follicle stimulating hormone [FSH]
value in the postmenopausal range) or b) surgically sterile (i.e., have had
hysterectomy, oophorectomy or tubal ligation)

- In good health based on medical history, laboratory tests and other assessments

- Body Mass Index (BMI) ≥19 and ≤32 kg/m^2

- Non-smoker or smokes ≤10 cigarettes/day or equivalent (2 pipes/day, 1 cigar/day) and
agrees not to smoke while confined at the study center

Exclusion Criteria:

- Mentally or legally incapacitated, has significant emotional problems at the time of
screening visit or expected during the conduct of the trial or has a history of
clinically significant psychiatric disorder of the last 5 years

- History of clinically significant endocrine, gastrointestinal, cardiovascular,
hematological, hepatic, immunological, renal, respiratory, genitourinary or major
neurological abnormalities or diseases

- History of cancer (malignancy)

- History of significant multiple and/or severe allergies (e.g., food, drug, latex
allergy), or has had an anaphylactic reaction or significant intolerability to
prescription or non-prescription drugs or food

- Positive for hepatitis B surface antigen, hepatitis C antibodies or human
immunodeficiency virus (HIV)

- Has had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL)
within 4 weeks prior to screening

- Has participated in another investigational trial within 4 weeks prior to screening

- Is unable to refrain from or anticipates the use of any medication, including
prescription and non-prescription drugs or herbal remedies beginning approximately 2
weeks prior to administration of the initial dose of trial drug, throughout the trial
(including washout intervals between treatment periods), until the post-study
follow-up visit

- Has received subcutaneous or sublingual immunotherapy within the past 1 year

- Consumes >3 glasses of alcoholic beverages per day

- Consumes excessive amounts, defined as >6 servings of coffee, tea, cola, energy
drinks, or other caffeinated beverages per day

- Currently a regular user (including "recreational use") of any illicit drugs or has a
history of drug (including alcohol) abuse within approximately 12 months

- Has a recollection of previously receiving sugammadex, Bridion™, SCH 900616, ORG
25969, or MK-8616

- History of chronic urticaria or angioedema

- Is or has an immediate family member (spouse or children) who is a member of
investigational site or sponsor staff directly involved with this trial